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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not psilocybin
is an effective treatment to reduce depression and anxiety in cancer patients with a diagnosis of
an anxiety disorder, mood disorder, and/or stress disorder.
Study design: Systematic review of three cross-over randomized placebo-controlled trials
published in peer reviewed journals between 2010-2016.
Data sources: All articles were published in English and were selected from Cochrane
Collaboration and PubMed based on if they were relevant to my clinical question and included
patient-oriented outcomes (POEMs).
Outcomes measured: Outcomes measured included self-reported anxiety and depression via the
State-Trait Anxiety Inventory (STAI) and the Beck Depression Inventory (BDI), respectively.
Results: Grob et al. (Arch Gen Psychiatry. 2011;68(1):71-78. doi: 10.1001/archgenpsychiatry.
2010.116) found that controlled use of psilocybin when compared with placebo improved selfreported anxiety (p<0.001) and depression (p=0.05) in cancer patients. Further study by Griffiths
et al. (J Psychopharmacol. 2016;30(12):1181-1197. doi: 0269881116675513) demonstrated that
a therapeutic dose of psilocybin can statistically significantly reduce both cancer-related anxiety
(p<0.01) and depression (p<0.05). Lastly, Ross et al. (J Psychopharmacol. 2016;30(12):11651180. doi: 0269881116675512 [pii]) found that single moderate dose psilocybin in conjunction
with psychotherapy produced statistically significant clinical benefits in terms of reduction of
anxiety (p<0.001) and depression (p<0.01) in patients with cancer and was significantly more
effective than placebo with psychotherapy.
Conclusion: All three randomized controlled trials found a statistically significant reduction in
self-reported anxiety via STAI scores when patients were treated with psilocybin versus placebo.
Two of the three studies reported a statistically significant decrease in self-reported depression
via BDI scores, with the third reporting substantial decrease but narrowly missing statistically
significance. Future studies should be done that are not cross-over design in order to improve
blinding and therefore validity of the study, and with larger, more diverse patient populations to
increase the generalizability of these results.
Key words: Psilocybin, Depression, Anxiety
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INTRODUCTION
Anxiety disorders cause feelings of excessive and persistent worry. Depression is a mood
disorder characterized by feelings of depressed mood or anhedonia. Although these disorders
affect many people in the general population, they are especially problematic for cancer patients.
Cancer patients are prone to developing chronic, clinically significant anxiety, depressed mood,
and/or decreased quality of life, with up to 40% of patients meeting the criteria for a mood
disorder.1 Anxiety and depression in cancer patients is associated with treatment non-adherence,
prolonged hospitalization, higher suicide rates, decreased quality of life, increased healthcare
utilization, and lower survival rates.1,2
Anxiety and depression in cancer patients poses significant cost and resource utilization
to the healthcare system. In 2014, depressed cancer patients had 113% higher total healthcare
costs than non-depressed cancer patients for the year.3 The average healthcare charges for
depressed patients was $235,337, while non-depressed patients averaged $110,650 annually.3
This includes higher expenses for depressed patients in ambulatory care, emergency department
costs, and hospital charges.3 There are no numbers reported for cost incurred due to anxiety
specifically in cancer patients. However, research in 2005 showed that a diagnosis of generalized
anxiety disorder increases healthcare costs by $2,138 per patient when controlling for other
factors such as demographics and other comorbidities.4 In addition, in 2011 the mean annual
number of healthcare visits for a depressed cancer patient was 29.3, which was significantly
different than that of a non-depressed cancer patient at 14.7.5
Although the exact mechanism is not fully understood, cancer patients often face
psychological, social, spiritual and existential crises as they cope with facing their own mortality,
which can lead to anxiety and depression disorders.6 The symptoms of anxiety and depression
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are affected by neurotransmitters in the brain such as serotonin, epinephrine, norepinephrine,
dopamine, and GABA. Symptoms of depression include anhedonia, fatigue, change in appetite,
irritability, pessimism, hopelessness, helplessness, sleep disturbances, feelings of shame/guilt,
and suicidal ideations. Symptoms of anxiety include apprehension, excess worry, irritability,
difficulty concentration, sleep disturbances, restlessness, and easy fatiguability.
The usual treatments for anxiety and depression include both psychotherapy and
pharmacotherapy. Psychotherapy may include cognitive behavioral therapy (CBT) or insightoriented therapy. First line pharmacotherapy for anxiety and depression is selective serotonin
reuptake inhibitors (SSRIs) such as paroxetine, sertraline, citalopram, and escitalopram. Other
pharmacotherapy options include serotonin–norepinephrine reuptake inhibitors (SNRIs) such as
duloxetine and venlafaxine. In addition, benzodiazepines may be prescribed for short-term or
breakthrough anxiety symptoms such as lorazepam, alprazolam, and diazepam.
Pharmacotherapy and psychosocial interventions used for anxiety and depression in
cancer patients have mixed and limited efficacy, and there is no current FDA-approved
pharmacotherapy for cancer-related psychological distress.2 Treatment effects of anti-depressants
have a delayed onset, and these drugs are associated with high relapse rates and significant side
effects that reduce treatment adherence in cancer patients.2 Recent research has explored the
possibility of using psilocybin, a naturally-occurring psychedelic compound found in certain
mushrooms, to treat such patients. In the United States, psilocybin is an illegal drug with no
current medical or pharmaceutical indications. The studies in this review explore whether
psilocybin can effectively reduce self-reported anxiety and depression in patients with cancer as
measured by the State-Trait Anxiety Inventory (STAI) and Beck Depression Inventory (BDI)
respectively. Psilocybin has the potential to offer a novel, naturally occurring and more effective
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treatment modality for these cancer patients who face significant anxiety and depression and
have limited treatment options available to them. The mounting evidence showing the efficacy of
psilocybin as a treatment for anxiety and depression in cancer patients is vital in order to shift
public opinion about this drug and to improve the possibility of psilocybin one day being a legal
pharmaceutical option for these patients in the United States. Improvement in treating anxiety
and depression in cancer patients could decrease psychological distress, increase treatment
adherence, decrease healthcare costs, and improve quality of life for these patients.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not psilocybin is
an effective treatment to reduce depression and anxiety in cancer patients with a diagnosis of an
anxiety disorder, mood disorder, and/or stress disorder.
METHODS
Three cross-over randomized placebo-controlled studies were selected in order to answer
the EBM question. The population in these studies was cancer patients with a diagnosis of
anxiety disorder, mood disorder, and/or stress disorder. The intervention was an active dose of
psilocybin, and the comparisons included niacin 250 mg or low placebo-like dose of psilocybin.
All articles were published in English in peer-reviewed journals between the years of
2010-2016. Keywords used during the search for these articles included “psilocybin”,
“depression”, and “anxiety”. Articles were selected from the databases Cochrane Collaboration
and PubMed based on if they were relevant to the clinical question and included patient-oriented
outcomes (POEMs). Inclusion criteria included patients with cancer and randomized placebocontrol trials. Exclusion criteria included studies published prior to 2010. Statistics used in the
studies consisted of Cohen’s d, t-score, and p-value. The studies chosen measured patient
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outcomes of self-reported anxiety and depression. Table 1 displays the demographics and
characteristics of the selected studies.
Table 1. Demographics & Characteristics of included studies
Study
Type
#
Age
Inclusion Criteria Exclusion Criteria
Pts (years)
Griffiths1 Cross- 51 Mean: Potentially life-Cancer with known
(2016)
over
56.3
threatening cancer CNS involvement
RCT
& DSM-IV
-Hepatic/renal
diagnosis of
dysfunction
chronic adjustment -Severe CV illness
disorder with
-Pregnancy
anxiety, chronic
-Epilepsy
adjustment
-History/1st degree
disorder with
relative with
mixed anxiety/
schizophrenia,
depressed mood,
bipolar or psychotic
dysthymic
disorder
disorder, GAD,
-History of alcohol/
and/or MDD
drug dependence
Ross2
Cross- 31 Mean: Potentially life-<8 on HADS scale
(2016)
over
56.28
threatening cancer -Epilepsy, renal
RCT
Range: with >1-year life
disease, DM, severe
expectancy &
CV disease, liver
22-75
DSM-IV diagnosis dysfunction
of Acute Stress
-History of bipolar,
Disorder, GAD,
schizophrenia,
Anxiety disorder
delusional, paranoid,
due to cancer, or
schizoaffective, or
Adjustment
substance use
disorder with
disorders
anxiety/depression
Grob6
Cross- 12 Range: Advanced-stage
-Cancer with CNS
(2011)
over
36-58
cancer & DSM-IV involvement
RCT
diagnosis of acute -Severe CV illness
stress disorder,
-Hepatic/renal
GAD, anxiety
dysfunction or DM
disorder due to
-Life-time history of
cancer, or
schizophrenia,
adjustment
bipolar disease, or
disorder with
psychotic illness
-Anxiety/affective
anxiety
disorder within 1
year

W/ InterD ventions
5
Active
psilocybin
dose (22
or 30
mg/
70kg)

6

Single
psilocybin
dosing
session
(0.3
mg/kg)
with
psychotherapy

4

Active
psilocybin
(0.2
mg/kg)
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-Chemotherapy,
antiseizure, hypoglycemic, or psychotropic meds in last 2
weeks
OUTCOMES MEASURED
This EBM review compares outcomes of the intervention group to the control group
through self-reported anxiety and depression. The outcomes were measured in all three studies
by self-reported anxiety via the State-Trait Anxiety Inventory (STAI) and self-reported
depression via the Beck Depression Inventory (BDI). The STAI is a psychological tool to
measure both state and trait anxiety with 20 of the questions concentrating on trait anxiety and 20
on state anxiety. The STAI trait anxiety score is the primary measurement of anxiety treatment
effects in this review. The BDI is a common psychological assessment that contains 21 questions
used for patients to self-rate the severity of their depressive symptoms.
RESULTS
All three studies used similar inclusion and exclusion criteria with no notable differences.
The subjects all had to be adults with a potentially life-threatening cancer diagnosis as well as a
DSM-IV diagnosis related to anxiety and/or depression.1,2,6 They could not have CNS or severe
end-organ involvement/dysfunction or have any history of psychiatric illness.1,2,6 More detailed
inclusion and exclusion criteria can be seen in table 1 for each study, however there are no
significant differences between the criteria.
The pilot study by Grob et al. in 2011 was a randomized placebo-controlled trial
comparing moderate dose (0.2 mg/kg) psilocybin to niacin 250 mg to treat depression and
anxiety in 12 cancer patients.6 In this study, the participants acted as their own control as it was a
cross-over design with each subject receiving both treatment and placebo in a randomized order.6
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Subjects were asked to self-report their anxiety and depression via the STAI and BDI one day
prior to treatment as well as at a 1 month follow up after treatment.6 These values were compared
using a 2-way analysis of variance (ANOVA) and treatment effects were expressed with t-score.6
At 1 month follow up after psilocybin treatment, STAI scores exhibited a statistically significant
decrease (p<0.001) as can be seen in Table 2.6 BDI scores, although not statistically significant
(p=0.05), still showed a substantial decrease in self-reported depression at 1 month posttreatment.6
In the study by Grob et al., the experimental sessions were performed in the controlled
environment of a hospital clinical research unit.6 During the sessions, subjects were left alone in
a room with occasional check-ins by treatment staff.6 After the 6-hour session was complete, the
subjects discussed their experience with the staff and completed the STAI and BDI
questionnaires.6 Subjects were then continually assessed up to 6 months after the study began.6
Eleven of the twelve study participants completed at least the first 4 months of assessments.6
Table 2. STAI and BDI scores in Grob et al6
1 day before
1 month after
treatment
treatment
(approximate mean) (approximate mean)
STAI Trait Score
43
36
BDI Score

15.5

9.5

T-score

P-value

4.36

p<0.001

-2.17

p=0.05

Building on the work of this pilot study, Griffith et al. and Ross et al. published larger
studies in 2016 using psilocybin to treat depression and anxiety in cancer patients. Griffiths et al.
was a randomized cross-over controlled trial comparing low placebo-like dose of psilocybin (1
or 3 mg/70 kg) to a high dose of psilocybin (22 or 30 mg/70 kg) in 51 subjects.1 The low dose
was decreased from 3 to 1 mg/70 kg after 12 subjects because of data from a dose-effect study
published by Griffiths et al. in 2011. This study showed significant psilocybin effects at a dose of
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5 mg/70 kg so there was concern that 3 mg/70 kg would be an active rather than a placebo dose.1
The active high dose was lowered from 30 to 22 mg/kg after 3 subjects because of this doseeffect study data and also because 2 out of 3 of the first participants discontinued the study, one
due to vomiting after pill administration and one due to “personal reasons”.1 At the conclusion of
the trial, the compliance rate at the end of 6-months of follow-ups was about 90%.1
Griffiths et al. had participants undergo treatment in a living-room-like environment in
the presence of two monitors who were blinded to treatment.1 Subjects were encouraged to lay
down wearing eye masks, and the same music was played for all participants.1 Griffiths et al.
found statistically significant decreases in both STAI scores (p<0.01) and BDI scores (p<0.05)
from baseline to 5 weeks post-treatment in their pre-crossover data set as seen in table 3.1 The
group of subjects who received low placebo-like dose first were used as a control and betweengroup treatment effects were measured using Cohen’s d.1 Cohen’s d revealed moderate
difference between groups for STAI scores and large difference between groups for BDI scores.1
Table 3. Pre-crossover STAI and BDI scores in Griffiths et al1
Baseline
5 weeks post-session for
(mean)
treatment group (mean)
STAI Trait Score
47.73
34.64
BDI Score

17.77

7.00

Cohen’s d

P-value

0.60

p<0.01

0.81

p<0.05

Lastly, Ross et al. (2016) published a randomized placebo-controlled crossover trial that
compares single dose psilocybin (0.3 mg/kg) to niacin (250 mg), both in combination with
psychotherapy to treat anxiety and depression in patients with cancer.2 During the experimental
sessions, 29 subjects were given either active psilocybin or placebo (niacin) in conjunction with
a psychotherapy session.2 The dosing sequence was randomized and sessions occurred 7 weeks
apart, with Cohen’s d being used to estimate between-group treatment effects.2 The resulting
statistically significant reduction in both BDI scores (p<0.01) and STAI scores (p<0.001) at 6
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weeks post-treatment for the first treatment group can be seen in table 4.2 Cohen’s d also showed
statistically significant large differences between treatment and control groups in both STAI and
BDI scores.2 Compliance rate at the conclusion of the study was about 79%, however this was
mostly due to disease progression in the subjects.2
Table 4. Decrease in pre-crossover STAI and BDI scores in Ross et al2
Baseline
6-week follow up for
Cohen’s d
(approximate
treatment group
mean)
(approximate mean)
STAI Trait Score
48
33
1.31
BDI Score

15

6.5

1.07

P-value
p<0.001
p<0.01

All three of these studies reported similar safety outcomes for psilocybin use and found
that overall it was very tolerable with minimal adverse events. The most common and most
significant adverse reaction in these three trials was cardiovascular effects through transient
increase in blood pressure (BP) and heart rate (HR) during the sessions.1,2,6 This adverse reaction
was expected based on prior research done regarding psilocybin use. Peaking at 2 hours postadministration, Grob et al. reported statistically significant increases in systolic and diastolic BP
as well as HR (table 5), while Griffiths et al. reported statistically significant increases in systolic
BP and HR (table 5).1,6 Ross et al. reported statistically significant elevation in mean systolic and
diastolic BP that peaked at 142/83 mmHg at 180 minutes post-dosing of psilocybin and a
statistically significant increase in mean HR that peaked at 71 bpm at 300 minutes post-dosing.2
Table 5. Mean BP and HR at 2 hours post-administration for treatment and control groups
Systolic BP (mmHg)
Diastolic BP (mmHg)
Heart Rate (bpm)

Grob et al6
Griffiths et al1

Treatment
group
145

Control
group
127

Treatment
group
81

Control
group
72

Treatment
group
76

Control
group
69

140

115

77

68

82

68
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DISCUSSION
Psilocybin is a tryptamine serotoninergic psychedelic that acts as a 5-HT2A receptor
agonist in active doses and produces alterations in thoughts, emotions and state of
consciousness.1,2,6 Psilocybin and its potential medicinal benefits have received very little
research possibly due to the fact that it is currently illegal to use or possess in the United States.
However, many cultures and religions throughout history have used psilocybin mushrooms for
both their hallucinogenic and medicinal effects. More recently, psilocybin is being studied for
several potential therapeutic uses in addition to anxiety and depression in cancer patients. For
example, one randomized controlled trial in 2006 found that psilocybin could be used safely to
produce a significant acute decrease in core obsessive compulsive disorders (OCD) symptoms in
9 subjects.7 Although psilocybin is not currently indicated for any medicinal use in the United
States, the people of Denver, Colorado voted in May 2019 to decriminalize psilocybin,
signifying a possible shift in the mindset of Americans about psilocybin. With limited existing
options and no FDA-approved treatment specifically for cancer-related anxiety and depression,
psilocybin offers a new potential treatment modality for the psychological distress that these
patients experience.
The pilot study published by Grob et al. in 2011 shed light on some of these medicinal
benefits, finding a statistically significant decrease in self-reported anxiety via STAI scores
(p<0.001) and substantial decline in self-reported depression via BDI although not statistically
significant (p=0.05) at 1 month post-treatment.6 This study had limited generalizability due to a
small sample size of 12 participants, 11 of whom were female, but results were promising and set
the stage for future research about the possible therapeutic benefits of psilocybin for cancer
patients.6
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Griffiths et al. and Ross et al. published larger and more thorough studies in 2016 using
psilocybin to treat anxiety and depression in cancer patients. Griffiths et al. used low placebolike dose psilocybin as a control, while Ross et al. used niacin 250 mg as a control with both
treatment and control groups receiving psychotherapy during sessions.1,2 Both studies found
statistically significant decreases in STAI and BDI scores as well as significant differences
between treatment and control groups.1,2 However, these two studies used a very high proportion
of white subjects, both over 90%.1,2 In addition, all three of the studies in the EBM review were
cross-over designs which limited blinding. Compliance rates in the studies ranged from 79-92%,
with the majority of withdrawals from each of the studies being due to disease progression.1,2,6
However, the withdrawals were not managed with worst case analysis.
CONCLUSION
When used in a controlled environment, psilocybin is effective in reducing depression
and anxiety in cancer patients with a diagnosis of an anxiety disorder, mood disorder, and/or
stress disorder. All three studies demonstrated statistically significant decreases in self-reported
STAI scores for anxiety. Two of three studies showed statistically significant decreases in BDI
scores for depression with the third having substantial decrease in BDI scores but narrowly
missing statistical significance (p=0.05). Future research should be aimed at having larger
sample sizes with a more diverse patient population to increase generalizability of the results.
With larger sample sizes, there would be no need for a crossover design allowing the studies to
be double-blinded, which would increase the validity of the results. The three studies in this
EBM review have shown promising results for the therapeutic use of psilocybin for anxiety and
depression in cancer patients. More comprehensive randomized controlled trials could increase
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the evidence supporting the safe and therapeutic use of psilocybin, providing cancer patients with
a new and more effective treatment for their anxiety and depression.
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